These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 30068368)
1. Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia. Ghelli Luserna Di Rorà A; Beeharry N; Imbrogno E; Ferrari A; Robustelli V; Righi S; Sabattini E; Verga Falzacappa MV; Ronchini C; Testoni N; Baldazzi C; Papayannidis C; Abbenante MC; Marconi G; Paolini S; Parisi S; Sartor C; Fontana MC; De Matteis S; Iacobucci I; Pelicci PG; Cavo M; Yen TJ; Martinelli G J Hematol Oncol; 2018 Aug; 11(1):99. PubMed ID: 30068368 [TBL] [Abstract][Full Text] [Related]
2. Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia. Ghelli Luserna Di Rorà A; Bocconcelli M; Ferrari A; Terragna C; Bruno S; Imbrogno E; Beeharry N; Robustelli V; Ghetti M; Napolitano R; Chirumbolo G; Marconi G; Papayannidis C; Paolini S; Sartor C; Simonetti G; Yen TJ; Martinelli G Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31717700 [TBL] [Abstract][Full Text] [Related]
3. Bortezomib Is Effective in the Treatment of T Lymphoblastic Leukaemia by Inducing DNA Damage, WEE1 Downregulation, and Mitotic Catastrophe. Din RU; Jiao A; Qiu Y; Mohan AAM; Yuen KC; Wong HT; Wan TM; Wong PO; Sin CF Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834095 [TBL] [Abstract][Full Text] [Related]
4. WEE1 inhibition induces glutamine addiction in T-cell acute lymphoblastic leukemia. Hu J; Wang T; Xu J; Wu S; Wang L; Su H; Jiang J; Yue M; Wang J; Wang D; Li P; Zhou F; Liu Y; Qing G; Liu H Haematologica; 2021 Jul; 106(7):1816-1827. PubMed ID: 31919076 [TBL] [Abstract][Full Text] [Related]
5. Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia. Ghelli Luserna Di Rorà A; Iacobucci I; Imbrogno E; Papayannidis C; Derenzini E; Ferrari A; Guadagnuolo V; Robustelli V; Parisi S; Sartor C; Abbenante MC; Paolini S; Martinelli G Oncotarget; 2016 Aug; 7(33):53377-53391. PubMed ID: 27438145 [TBL] [Abstract][Full Text] [Related]
13. Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer. Sen T; Tong P; Diao L; Li L; Fan Y; Hoff J; Heymach JV; Wang J; Byers LA Clin Cancer Res; 2017 Oct; 23(20):6239-6253. PubMed ID: 28698200 [No Abstract] [Full Text] [Related]
14. Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies. Friedman J; Morisada M; Sun L; Moore EC; Padget M; Hodge JW; Schlom J; Gameiro SR; Allen CT J Immunother Cancer; 2018 Jun; 6(1):59. PubMed ID: 29925431 [TBL] [Abstract][Full Text] [Related]
15. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma. Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911 [TBL] [Abstract][Full Text] [Related]
16. Genetic inhibition of the atypical kinase Wee1 selectively drives apoptosis of p53 inactive tumor cells. Pappano WN; Zhang Q; Tucker LA; Tse C; Wang J BMC Cancer; 2014 Jun; 14():430. PubMed ID: 24927813 [TBL] [Abstract][Full Text] [Related]
17. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint. Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437 [TBL] [Abstract][Full Text] [Related]
18. Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. Weisberg E; Nonami A; Chen Z; Liu F; Zhang J; Sattler M; Nelson E; Cowens K; Christie AL; Mitsiades C; Wong KK; Liu Q; Gray N; Griffin JD Leukemia; 2015 Jan; 29(1):27-37. PubMed ID: 24791855 [TBL] [Abstract][Full Text] [Related]
19. A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations. Zhou L; Zhang Y; Chen S; Kmieciak M; Leng Y; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Dai Y; Grant S Leukemia; 2015 Apr; 29(4):807-18. PubMed ID: 25283841 [TBL] [Abstract][Full Text] [Related]
20. Chk1 and Wee1 control genotoxic-stress induced G2-M arrest in melanoma cells. Vera J; Raatz Y; Wolkenhauer O; Kottek T; Bhattacharya A; Simon JC; Kunz M Cell Signal; 2015 May; 27(5):951-60. PubMed ID: 25683911 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]